ATE237587T1 - 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten - Google Patents

11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Info

Publication number
ATE237587T1
ATE237587T1 AT98901576T AT98901576T ATE237587T1 AT E237587 T1 ATE237587 T1 AT E237587T1 AT 98901576 T AT98901576 T AT 98901576T AT 98901576 T AT98901576 T AT 98901576T AT E237587 T1 ATE237587 T1 AT E237587T1
Authority
AT
Austria
Prior art keywords
derivatives
dialkylprostaglandin
production
active ingredients
products containing
Prior art date
Application number
AT98901576T
Other languages
English (en)
Inventor
Shuichi Ohuchida
Takayuki Maruyama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE237587T1 publication Critical patent/ATE237587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98901576T 1997-02-10 1998-02-10 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten ATE237587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4157197 1997-02-10
PCT/JP1998/000544 WO1998034916A1 (fr) 1997-02-10 1998-02-10 Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif

Publications (1)

Publication Number Publication Date
ATE237587T1 true ATE237587T1 (de) 2003-05-15

Family

ID=12612138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901576T ATE237587T1 (de) 1997-02-10 1998-02-10 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Country Status (10)

Country Link
US (1) US6288119B1 (de)
EP (1) EP1008588B1 (de)
JP (1) JP4044967B2 (de)
KR (1) KR20000070903A (de)
AT (1) ATE237587T1 (de)
DE (1) DE69813571T2 (de)
DK (1) DK1008588T3 (de)
ES (1) ES2196527T3 (de)
PT (1) PT1008588E (de)
WO (1) WO1998034916A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2004032964A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. アレルギー性疾患治療剤
DK1563846T3 (da) 2002-10-10 2012-12-17 Ono Pharmaceutical Co Endogene reparationsfaktorproduktionsfremmere
WO2004074842A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
US20070167403A1 (en) * 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
WO2005009468A1 (ja) 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
US7833995B2 (en) * 2003-12-05 2010-11-16 Ono Pharmaceutical Co., Ltd. Blood flow promoters for cauda equina tissues
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
CA2610692C (en) 2005-06-03 2014-11-25 Ono Pharmaceutical Co., Ltd. Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
RU2009117605A (ru) * 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) ПРОИЗВОДНЫЕ СПИРО-(ФУРО[3,2-c]ПИРИДИН-3-3'-ИНДОЛ)-2'(1'H)-ОНА И РОДСТВЕННЫЕ ИМ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ НАТРИЕВЫМИ КАНАЛАМИ ЗАБОЛЕВАНИЙ, ТАКИХ КАК БОЛЬ
WO2009065081A2 (en) 2007-11-14 2009-05-22 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
WO2010045251A2 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
BRPI1013152B1 (pt) 2009-06-10 2019-06-18 Ono Pharmaceutical Co., Ltd. Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
AU2013246485A1 (en) 2012-04-12 2014-10-16 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
AU2013309872B2 (en) 2012-08-31 2017-09-14 Ono Pharmaceutical Co., Ltd. Amine salt and crystals thereof
EP2968264A4 (de) 2013-03-14 2016-11-02 Celtaxsys Inc Inhibitoren der leukotrien-a4-hydrolase
EP2818484A1 (de) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistische Kombination eines Anti-IgE-Antikörpers und eines EP2-Rezeptoragonisten
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
KR20190088551A (ko) 2016-12-09 2019-07-26 켈탁시스, 인코퍼레이티드 루코트리엔 a4 하이드롤라제의 저해제
CA3045887A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
AU2017371353B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835180A (en) * 1971-05-04 1974-09-10 Upjohn Co 15 alkoxy pge compounds
US3876690A (en) * 1973-05-11 1975-04-08 American Cyanamid Co 1-alkoxy-9-keto-prostenoic acid derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
US4236027A (en) * 1977-10-17 1980-11-25 American Cyanamid Company Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same
JPS55115836A (en) * 1979-03-02 1980-09-06 Toray Ind Inc Preparation of methyl ether derivative
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤

Also Published As

Publication number Publication date
ES2196527T3 (es) 2003-12-16
JP4044967B2 (ja) 2008-02-06
DK1008588T3 (da) 2003-07-28
EP1008588A4 (de) 2000-06-14
EP1008588B1 (de) 2003-04-16
WO1998034916A1 (fr) 1998-08-13
US6288119B1 (en) 2001-09-11
EP1008588A1 (de) 2000-06-14
DE69813571D1 (de) 2003-05-22
KR20000070903A (ko) 2000-11-25
DE69813571T2 (de) 2004-02-12
PT1008588E (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
ATE237587T1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
DE60137442D1 (de) 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
ATE19236T1 (de) (omega-(diaethylamino)-alkoxy)-alpha-(aethyl)benzhydrolderivate, ihre saeureadditionssalze und quaternaeren salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
DE50204789D1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
CA2373962A1 (en) Immediate release medicinal compositions for oral use
ATE223717T1 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
DK0805817T3 (da) Thiolderivater med metallopeptidaseinhiberende aktivitet
BR0109252A (pt) Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição
ATE178901T1 (de) Anthracyclin-disaccharide, verfahren zu ihrer herstellung, und diese enthaltende arzneimittel
CA2267247A1 (fr) Heteroaryloxyethylamines en tant que ligands 5-ht1a
ATE265459T1 (de) Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1008588

Country of ref document: EP

REN Ceased due to non-payment of the annual fee